Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.
复制标题
先前全身治疗失败后，用于治疗晚期转移性肾细胞癌（MRCC）患者的Axitinib。
DOI：
10.2147/ott.s23273
复制
发表时间：
2012
影响因子：
4
通讯作者：
Merseburger AS
中科院分区：
文献类型：
--
作者：
Grünwald V;Merseburger AS
近年来，肾细胞癌(RCC)的治疗格局发生了巨大的变化。贝伐单抗/干扰素、舒尼替尼、索拉非尼、替西罗莫司、伊维洛莫斯和帕佐帕尼已被证明对转移性肾癌有效。Axitinib是一种新型的酪氨酸激酶抑制剂，在亚纳摩尔水平上抑制血管内皮生长因子受体(VEGFR)。基于这种特殊的VEGFR抑制作用，阿西替尼被认为是下一代药物。最近的Axis试验报告了axitinib在肾癌二线治疗中的疗效，这导致它最近在美国获得批准。现就阿西替尼治疗肾癌的临床疗效作一综述。
The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib’s efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.